PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today its financial results for the fourth quarter and year ended December 31, 2011.
“In 2011, we completed enrollment in two Phase 3 trials of tavaborole in onychomycosis, which keeps us on track to announce top-line data from the first of these trials around the end of 2012 and from the second trial in the beginning of 2013,” said David Perry, CEO of Anacor Pharmaceuticals. “In addition, in December 2011, we successfully completed a Phase 2a study of AN2728 in atopic dermatitis, which provided us with positive data that, when combined with the safety and efficacy demonstrated in 13 other clinical trials, supports our plan to conduct additional Phase 2 studies of AN2728 in atopic dermatitis in 2012.”
